Dr. Drake Discusses the Results of the CARMENA Study in RCC

Charles G. Drake, MD, PhD
Published: Wednesday, Aug 01, 2018



Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the results of the CARMENA study in patients with metastatic renal cell carcinoma (mRCC).

Results from the phase III CARMENA trial demonstrated the noninferiority of sunitinib (Sutent) alone compared with cytoreductive nephrectomy followed by sunitinib in patients with intermediate- and high-risk disease. Drake says that these results? were surprising, and these approaches were statistically equivalent in terms of overall survival.

Drake believes that the findings from this trial will generally reduce the use of cytoreductive nephrectomy. Nevertheless, the question of patient selection remains. There are some people in the field who believe that they can select patients who will benefit from cytoreductive nephrectomy, Drake says. Overall, cytoreductive nephrectomy is not going anywhere, but global use will go down, Drake concludes.
SELECTED
LANGUAGE


Charles G. Drake, MD, PhD, director of Genitourinary Oncology, NewYork-Presbyterian/Columbia University Medical Center and co-director of Columbia’s Cancer Immunotherapy Programs, discusses the results of the CARMENA study in patients with metastatic renal cell carcinoma (mRCC).

Results from the phase III CARMENA trial demonstrated the noninferiority of sunitinib (Sutent) alone compared with cytoreductive nephrectomy followed by sunitinib in patients with intermediate- and high-risk disease. Drake says that these results? were surprising, and these approaches were statistically equivalent in terms of overall survival.

Drake believes that the findings from this trial will generally reduce the use of cytoreductive nephrectomy. Nevertheless, the question of patient selection remains. There are some people in the field who believe that they can select patients who will benefit from cytoreductive nephrectomy, Drake says. Overall, cytoreductive nephrectomy is not going anywhere, but global use will go down, Drake concludes.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x